Global Venous Thromboembolism Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Venous Thromboembolism Market Size

• The global venous thromboembolism market size was valued at USD 7.50 billion in 2025 and is expected to reach USD 11.38 billion by 2033, at a CAGR of 5.36% during the forecast period
• The market growth is largely fueled by the rising incidence of venous disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE), along with increasing prevalence of risk factors including obesity, cancer, prolonged immobility, and aging populations, leading to greater demand for effective prevention and treatment solutions across healthcare settings
• Furthermore, growing awareness of early diagnosis, rising adoption of anticoagulant therapies, and increasing use of compression devices and advanced diagnostic imaging are establishing Venous Thromboembolism management as a critical component of cardiovascular care. These converging factors are accelerating the uptake of Venous Thromboembolism solutions, thereby significantly boosting the industry's growth

Venous Thromboembolism Market Analysis

• Venous Thromboembolism (VTE) management solutions, including anticoagulant drugs, thrombolytic therapies, compression devices, and advanced diagnostic systems, are increasingly vital components of modern cardiovascular and critical care management due to their role in preventing and treating deep vein thrombosis and pulmonary embolism across hospitals, specialty clinics, and emergency care settings
• The escalating demand for Venous Thromboembolism solutions is primarily fueled by the rising incidence of lifestyle-related risk factors such as obesity, cancer, prolonged immobility, surgical procedures, and aging populations, along with increasing awareness regarding early diagnosis and preventive care strategies
• North America dominated the venous thromboembolism market with the largest revenue share of approximately 42.3% in 2025, characterized by advanced healthcare infrastructure, high diagnosis and treatment rates, strong clinical guidelines, and the presence of leading pharmaceutical companies, with the U.S. experiencing substantial growth in anticoagulant therapies and preventive VTE management programs
• Asia-Pacific is expected to be the fastest growing region in the venous thromboembolism market during the forecast period due to improving healthcare infrastructure, rising patient population, increasing surgical procedures, growing awareness of thrombotic disorders, and expanding access to advanced treatment options across China, India, Japan, and Southeast Asia
• The anti-clotting medications segment accounted for the largest market revenue share of 61.2% in 2025, driven by widespread use of anticoagulants such as heparin, warfarin, and direct oral anticoagulants (DOACs)

Report Scope and Venous Thromboembolism Market Segmentation 

Venous Thromboembolism Market Trends

“Enhanced Clinical Precision Through AI-Driven Risk Stratification and Digital Monitoring”

• A significant and accelerating trend in the global Venous Thromboembolism (VTE) market is the increasing integration of artificial intelligence (AI), predictive analytics, and digital health monitoring systems to improve early risk detection, diagnosis, and patient management. These technologies are enhancing clinical decision-making and reducing preventable thromboembolic events
• AI-based clinical decision support systems are increasingly being used to identify high-risk hospitalized patients by analyzing electronic health records, mobility patterns, and laboratory data
• For instance, hospitals in the U.S. and Europe are deploying AI-enabled alert systems within electronic medical record platforms to flag patients at elevated risk of deep vein thrombosis (DVT) or pulmonary embolism
• The growing use of wearable health monitoring devices is also enabling continuous tracking of patient mobility and physiological indicators, helping clinicians identify prolonged immobility—a key risk factor for VTE
• Another key trend is the adoption of digital anticoagulation management tools that support personalized dosing, monitor INR levels, and improve adherence to therapy in patients on long-term anticoagulant treatment
• In addition, advanced imaging techniques and biomarker-based diagnostics are improving the speed and accuracy of VTE detection, enabling earlier intervention and better clinical outcomes
• This shift toward predictive, data-driven, and continuously monitored care models is fundamentally transforming VTE management and improving patient safety across healthcare systems

Venous Thromboembolism Market Dynamics

Driver

“Rising Hospitalization Rates and Increasing Surgical Procedures”

• The increasing number of hospitalizations, surgical interventions, and trauma cases is a major driver for the Venous Thromboembolism market, as immobility and post-operative conditions significantly elevate VTE risk
• Growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and respiratory conditions further increases patient susceptibility to thromboembolic events
• For instance, cancer patients undergoing chemotherapy are at significantly higher risk of developing VTE, driving demand for preventive anticoagulant therapies
• Expanding awareness among healthcare providers regarding VTE prophylaxis is also supporting wider adoption of anticoagulants such as heparin, direct oral anticoagulants (DOACs), and low-molecular-weight heparin
• Furthermore, improved hospital protocols, surgical safety guidelines, and thromboprophylaxis programs in developed healthcare systems are contributing to increased treatment uptake
• The rising aging population globally, particularly in regions such as the U.S., Europe, and Japan, is further expanding the at-risk patient pool

Restraint/Challenge

“Bleeding Risks, Treatment Complexity, and High Cost of Long-Term Therapy”

• One of the major challenges restraining the Venous Thromboembolism market is the risk of bleeding complications associated with anticoagulant therapy, which requires careful monitoring and dose adjustment
• Treatment management can be complex, especially in elderly patients or those with multiple comorbidities, increasing the risk of adverse drug interactions and non-adherence
• For instance, patients on warfarin therapy often require frequent INR monitoring and dietary restrictions, which can complicate long-term treatment adherence
• High cost of long-term anticoagulation therapy, particularly with newer direct oral anticoagulants, can also limit accessibility in cost-sensitive healthcare systems
• In addition, underdiagnosis of VTE in early stages and variability in clinical presentation may delay treatment initiation, increasing morbidity and mortality risks
• Overcoming these barriers through safer anticoagulant options, improved patient monitoring, standardized clinical guidelines, and wider insurance coverage will be essential for sustained market growth

Venous Thromboembolism Market Scope

The market is segmented on the basis of product, type, treatment, end-users, and distribution channel.

• By Product

On the basis of product, the Venous Thromboembolism market is segmented into non-segmented pneumatic compression pumps, segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, upper pneumatic compression sleeves, lower pneumatic compression sleeves, permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, and catheter-directed thrombolysis (CDT) devices. The lower pneumatic compression sleeves segment dominated the largest market revenue share of 18.6% in 2025, driven by their widespread use in deep vein thrombosis (DVT) prevention in hospitalized and post-surgical patients. These devices are highly effective in improving venous blood flow in the lower extremities, significantly reducing clot formation risk. Hospitals extensively adopt them as part of standard prophylaxis protocols, particularly in orthopedic and surgical wards. Their non-invasive nature, ease of application, and compatibility with long-term immobilized patients further strengthen demand. Increasing awareness of hospital-acquired thrombosis prevention is also supporting adoption. Strong clinical guideline recommendations for mechanical prophylaxis contribute to widespread usage. Growing surgical volumes globally are further expanding patient base. Technological advancements in pressure calibration and portability enhance usability. Rising geriatric population with mobility issues adds to demand. Healthcare systems increasingly integrate these devices into routine care pathways. These factors collectively ensure segment dominance in 2025.

The catheter-directed thrombolysis (CDT) devices segment is anticipated to witness the fastest growth rate of 10.8% from 2026 to 2033, driven by increasing preference for minimally invasive, targeted clot-dissolving procedures. CDT devices allow precise delivery of thrombolytic agents directly into the clot, improving treatment effectiveness while reducing systemic bleeding risks. Growing incidence of pulmonary embolism and severe DVT cases requiring advanced intervention is supporting demand. Hospitals are increasingly adopting image-guided interventional radiology techniques. Rising investments in catheterization labs and vascular centers are boosting procedural capacity. Clinical evidence demonstrating improved outcomes compared to systemic thrombolysis is encouraging adoption. Technological improvements in catheter design and drug delivery efficiency are also supporting growth. Expansion of trained interventional specialists globally further strengthens uptake. Increasing preference for limb-salvage and complication-reducing therapies is accelerating usage. Aging populations with higher clot risk are expanding the eligible patient base. These factors position CDT devices as the fastest-growing product segment.

• By Type

On the basis of type, the Venous Thromboembolism market is segmented into deep vein thrombosis, pulmonary embolism, and others. The deep vein thrombosis (DVT) segment held the largest market revenue share of 54.3% in 2025, driven by its high global incidence, particularly among hospitalized, post-surgical, and immobile patients. DVT remains the most commonly diagnosed form of venous thromboembolism due to prolonged bed rest, cancer prevalence, obesity, and aging populations. Hospitals routinely screen high-risk patients for DVT using ultrasound and D-dimer testing. Increasing awareness of early symptoms such as limb swelling and pain is improving detection rates. Strong emphasis on preventive care in surgical and intensive care units is further supporting demand. Clinical guidelines recommend both mechanical and pharmacological prophylaxis for DVT prevention. Rising orthopedic and abdominal surgical procedures globally also contribute significantly. Improved diagnostic imaging technologies have enhanced identification rates. Growing burden of lifestyle-related risk factors continues to expand patient pool. Healthcare infrastructure expansion in emerging economies supports diagnosis and treatment access. These factors ensure strong dominance of the DVT segment.

The pulmonary embolism (PE) segment is expected to witness the fastest CAGR of 9.7% from 2026 to 2033, driven by increasing awareness of life-threatening complications associated with undiagnosed or untreated venous clots. PE is a critical condition requiring immediate intervention, leading to growing demand for advanced imaging, anticoagulant therapy, and catheter-based treatments. Rising prevalence of cardiovascular diseases and obesity is increasing PE risk globally. Improved emergency care systems and rapid diagnostic CT pulmonary angiography are enhancing detection rates. Hospitals are strengthening acute care protocols for faster intervention. Awareness campaigns among clinicians are improving early recognition of symptoms. Growing ICU admissions for severe PE cases are also driving treatment demand. Advancements in thrombolytic therapies and mechanical thrombectomy devices are supporting better outcomes. Increasing geriatric population further contributes to risk burden. Expanding healthcare access in developing regions is improving diagnosis rates. These factors position PE as the fastest-growing type segment.

• By Treatment

On the basis of treatment, the Venous Thromboembolism market is segmented into anti-clotting medications, mechanical devices, thrombolytic therapy, and others. The anti-clotting medications segment accounted for the largest market revenue share of 61.2% in 2025, driven by widespread use of anticoagulants such as heparin, warfarin, and direct oral anticoagulants (DOACs). These medications remain the first-line treatment for both prevention and management of VTE conditions. Physicians prefer anticoagulants due to their proven efficacy in reducing clot progression and recurrence. Increasing hospitalization rates and surgical procedures are boosting prophylactic use. Strong clinical guidelines support long-term anticoagulation therapy in high-risk patients. Availability of oral anticoagulants has improved patient compliance and outpatient management. Growing awareness of VTE risks in chronic disease patients further supports adoption. Expansion of insurance coverage in developed markets ensures affordability. Continuous drug innovation is improving safety profiles and reducing bleeding risks. Elderly populations requiring long-term therapy also contribute to demand. Hospital and retail pharmacies widely distribute these medications globally. These factors sustain segment leadership.

The thrombolytic therapy segment is anticipated to witness the fastest CAGR of 10.3% from 2026 to 2033, driven by increasing use in severe and life-threatening VTE cases such as massive pulmonary embolism. Thrombolytics provide rapid clot dissolution, restoring blood flow and reducing mortality risk. Growing adoption in emergency care settings and ICUs is supporting demand. Advances in drug formulations with improved safety profiles are increasing physician confidence. Catheter-based thrombolysis is also expanding usage in targeted therapies. Rising awareness of early aggressive intervention in critical patients is boosting adoption. Expansion of stroke and cardiovascular emergency centers further supports growth. Improved diagnostic speed enables timely thrombolytic administration. Increasing clinical trials are validating efficacy in broader patient groups. Growing geriatric population with high-risk profiles is contributing to demand. These factors make thrombolytic therapy the fastest-growing treatment segment.

• By End-Users

On the basis of end-users, the Venous Thromboembolism market is segmented into hospitals, homecare, speciality centres, and others. The hospitals segment dominated the largest market revenue share of 58.9% in 2025, driven by high patient admissions for surgery, trauma care, cancer treatment, and critical illnesses associated with VTE risk. Hospitals are the primary centers for diagnosis, acute treatment, and emergency management of DVT and PE cases. Availability of advanced imaging systems and interventional facilities strengthens hospital dominance. Standardized prophylaxis protocols in inpatient settings support mechanical and pharmacological prevention strategies. High surgical volumes, particularly orthopedic and cardiovascular procedures, increase risk exposure. Presence of multidisciplinary care teams enhances treatment outcomes. Government and insurance reimbursement systems favor hospital-based care. Continuous monitoring and ICU availability are essential for severe cases. Strong pharmaceutical procurement systems ensure drug availability. Public health initiatives further strengthen hospital-based screening programs. These factors collectively ensure market leadership.

The homecare segment is expected to witness the fastest CAGR of 11.5% from 2026 to 2033, driven by increasing preference for outpatient management and long-term anticoagulation therapy at home. Patients on oral anticoagulants are increasingly managed through telemedicine consultations. Growing adoption of home monitoring devices such as portable INR testing kits is supporting safe therapy. Aging populations prefer home-based care for chronic disease management. Rising healthcare costs encourage shift from hospital to home settings. Improved patient education on medication adherence is enhancing outcomes. Retail and online pharmacies are facilitating doorstep drug delivery. Post-discharge care programs are expanding globally. Digital health platforms are enabling remote monitoring of VTE patients. Government initiatives promoting decentralized healthcare further support growth. These factors make homecare the fastest-growing end-user segment.

• By Distribution Channel

On the basis of distribution channel, the Venous Thromboembolism market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment held the largest market revenue share of 52.4% in 2025, driven by high inpatient treatment volumes and immediate availability of anticoagulants, thrombolytics, and supportive therapies. Hospital pharmacies play a critical role in emergency care and post-surgical prophylaxis. Centralized procurement systems ensure continuous drug supply. Integration with clinical protocols improves treatment accuracy. High dependency on injectable anticoagulants supports hospital-based dispensing. ICU and emergency departments contribute significantly to demand. Strong regulatory oversight ensures safe medication use. Hospitals also manage complex dosing regimens for high-risk patients. Public healthcare infrastructure expansion supports segment growth. Physician-led prescribing patterns reinforce hospital channel dominance. Insurance reimbursement systems favor institutional dispensing. These factors sustain leadership in 2025.

The online pharmacy segment is expected to witness the fastest CAGR of 12.6% from 2026 to 2033, driven by increasing adoption of digital healthcare platforms and long-term oral anticoagulant therapy needs. Patients prefer online channels for regular refill medications due to convenience and cost savings. Telemedicine growth is increasing electronic prescription usage. Smartphone penetration is expanding access in both urban and rural areas. Subscription-based medicine delivery improves adherence. Online platforms offer price transparency and wider product availability. Improved logistics networks ensure timely drug delivery. Elderly patients benefit from home delivery services. Awareness of e-health services is growing rapidly. Regulatory support for digital pharmacies is improving in several countries. Contactless healthcare trends continue to rise globally. These factors make online pharmacy the fastest-growing distribution channel.

Venous Thromboembolism Market Regional Analysis

• North America dominated the venous thromboembolism market with the largest revenue share of approximately 42.3% in 2025, driven by advanced healthcare infrastructure, high diagnosis and treatment rates, and strong adherence to clinical guidelines across the region
• The presence of leading pharmaceutical companies and established hospital networks significantly supports market expansion. Rising incidence of deep vein thrombosis and pulmonary embolism is increasing demand for effective anticoagulant therapies. Strong adoption of preventive care protocols in hospitals and surgical centers further strengthens market growth. Continuous innovation in oral anticoagulants and injectable therapies is improving treatment outcomes
• High awareness among physicians regarding early diagnosis and risk management supports timely intervention. Government-backed healthcare programs and insurance coverage enhance patient access to treatment. Increasing focus on post-surgical thrombosis prevention is further driving demand. North America is expected to maintain its leading position throughout the forecast period

U.S. Venous Thromboembolism Market Insight

The U.S. venous thromboembolism market captured the largest revenue share in 2025 within North America, fueled by strong growth in anticoagulant therapies and preventive VTE management programs. The country has a high burden of risk factors such as obesity, cancer, aging population, and prolonged hospitalization, contributing to increased VTE cases. Advanced healthcare systems enable early diagnosis through imaging and biomarker-based testing. Strong physician adoption of novel oral anticoagulants (NOACs) is significantly boosting treatment uptake. Hospitals are implementing strict thromboprophylaxis guidelines for surgical and immobilized patients. Pharmaceutical companies are actively investing in safer and more effective anticoagulation therapies. Increasing awareness campaigns about blood clot prevention are improving patient outcomes. Strong reimbursement policies support widespread access to treatment options. The U.S. remains the primary revenue contributor in the regional market.

Europe Venous Thromboembolism Market Insight

The Europe venous thromboembolism market is projected to expand at a substantial CAGR throughout the forecast period, driven by strong healthcare systems and increasing awareness of thrombotic disorders. Rising hospitalization rates and surgical procedures are contributing to higher VTE incidence. Governments across the region are implementing clinical guidelines for thrombosis prevention in hospitals. Availability of advanced anticoagulant drugs and diagnostic tools supports market growth. Countries such as Germany, France, the U.K., and Italy are key contributors to regional expansion. Strong focus on patient safety and postoperative care is increasing prophylactic treatment adoption. Growing elderly population further raises risk of thromboembolic conditions. Continuous improvements in hospital care protocols are enhancing prevention strategies. Europe maintains a well-regulated and highly structured VTE management landscape.

U.K. Venous Thromboembolism Market Insight

The U.K. venous thromboembolism market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by NHS-led thrombosis prevention initiatives and strong clinical awareness. Increasing incidence of hospital-acquired VTE is promoting preventive screening programs. Widespread adoption of anticoagulant therapies in surgical and high-risk patients is supporting growth. Strong clinical guidelines ensure standardized treatment protocols across healthcare facilities. Rising elderly population and chronic disease burden are increasing VTE risk. Expansion of diagnostic capabilities is improving early detection rates. Government focus on patient safety and quality care is further strengthening prevention strategies. Research collaborations in cardiovascular medicine are supporting innovation. The U.K. continues to be a key European market for VTE management.

Germany Venous Thromboembolism Market Insight

The Germany venous thromboembolism market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced hospital infrastructure and strong clinical expertise. Germany has high adoption of evidence-based guidelines for thrombosis prevention and treatment. Increasing surgical volumes and aging population are key drivers of demand. Strong availability of anticoagulant drugs supports effective treatment management. Physicians are increasingly adopting newer oral anticoagulants for long-term therapy. Government healthcare policies emphasize preventive care and patient safety. Rising awareness regarding deep vein thrombosis and pulmonary embolism is improving diagnosis rates. Digital healthcare systems are enhancing patient monitoring and follow-up care. Germany remains a major contributor to the European VTE market.

Asia-Pacific Venous Thromboembolism Market Insight

The Asia-Pacific venous thromboembolism market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by improving healthcare infrastructure and rising surgical procedures. Increasing awareness of thrombotic disorders among healthcare professionals and patients is boosting diagnosis rates. Growing burden of chronic diseases such as cancer, obesity, and cardiovascular disorders is increasing VTE risk. Expansion of hospital facilities and intensive care units is improving treatment access. Governments across China, India, Japan, and Southeast Asia are investing in healthcare modernization. Rising adoption of anticoagulant therapies is supporting market growth. Increasing availability of affordable generic drugs is enhancing accessibility. Growing medical tourism in the region further strengthens demand. Asia-Pacific is expected to remain the fastest growing regional market.

Japan Venous Thromboembolism Market Insight

The Japan venous thromboembolism market is gaining momentum due to the country’s aging population and advanced healthcare system. High prevalence of chronic diseases and prolonged hospitalization increases VTE risk. Strong clinical adherence to preventive anticoagulation guidelines supports market growth. Increasing use of novel oral anticoagulants is improving treatment outcomes. Government healthcare programs emphasize early diagnosis and prevention strategies. Advanced hospital infrastructure enables effective management of thrombotic conditions. Rising awareness among physicians and patients supports early intervention. Integration of digital monitoring tools enhances post-treatment care. Japan is expected to show steady growth during the forecast period.

China Venous Thromboembolism Market Insight

The China venous thromboembolism market accounted for the largest market revenue share in Asia Pacific in 2025, driven by rapid expansion of healthcare infrastructure and increasing surgical volumes. Growing prevalence of cancer, cardiovascular diseases, and obesity is contributing to rising VTE cases. Government investments in hospital modernization and critical care units are improving treatment access. Increasing awareness of thrombotic disorders is enhancing early diagnosis rates. Expansion of pharmaceutical manufacturing is improving availability of anticoagulant therapies. Rising adoption of clinical guidelines in tertiary hospitals supports standardized care. Growth in private healthcare services further boosts accessibility. Continuous healthcare reforms are strengthening disease management systems. China is expected to remain a key driver of regional growth.

Venous Thromboembolism Market Share

The Venous Thromboembolism industry is primarily led by well-established companies, including:

• Bayer AG (Germany)
• Pfizer Inc. (U.S.)
• Bristol Myers Squibb (U.S.)
• Johnson & Johnson (U.S.)
• Sanofi S.A. (France)
• Boehringer Ingelheim International GmbH (Germany)
• Daiichi Sankyo Company, Limited (Japan)
• GlaxoSmithKline plc (U.K.)
• Abbott Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AstraZeneca plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Viatris Inc. (U.S.)
• Amgen Inc. (U.S.)
• Medtronic plc (Ireland)
• Becton, Dickinson and Company (U.S.)
• Boston Scientific Corporation (U.S.)

Latest Developments in Global Venous Thromboembolism Market

• In March 2021, the European Society for Vascular Surgery (ESVS) updated its clinical practice guidelines for venous thrombosis management, strengthening the recommendation of direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban as first-line therapy for most patients with deep vein thrombosis (DVT) and pulmonary embolism (PE). The update reinforced the global shift away from warfarin toward DOAC-based outpatient treatment strategies
• In March 2023, the U.S. Food and Drug Administration approved Vowst (fecal microbiota spores, live-brpk), developed by Seres Therapeutics, for the prevention of recurrent Clostridioides difficile infection, indirectly influencing VTE care pathways by reducing hospitalization-associated thrombotic complications linked with severe infections and prolonged antibiotic use. The approval highlighted increasing integration of microbiome-based therapies in infection-related thrombosis prevention contexts
• In April 2023, Bristol Myers Squibb and Pfizer continued expanding Eliquis® (apixaban) access programs globally, strengthening its dominance in the venous thromboembolism treatment market as the leading oral anticoagulant. The expansion of patient access and real-world evidence programs reinforced apixaban’s position as a preferred first-line therapy for DVT and PE prevention and treatment across multiple healthcare systems
• In September 2023, the U.S. Food and Drug Administration approved updated labeling for several direct oral anticoagulants, reinforcing their use for extended prevention of recurrent venous thromboembolism in high-risk patients. This regulatory update supported longer-duration anticoagulation strategies in clinical practice, expanding the commercial scope of VTE therapeutics
• In April 2024, major clinical research updates from cardiovascular studies confirmed the increasing adoption of factor Xa inhibitors over traditional anticoagulants due to improved safety profiles and lower bleeding risk in venous thromboembolism patients. These findings further strengthened guideline adoption of DOAC-based treatment regimens globally
• In April 2025, the U.S. Food and Drug Administration expanded approval for apixaban (Eliquis®) to include treatment and prevention of recurrent venous thromboembolism in pediatric patients following initial anticoagulant therapy. This marked a significant expansion of the VTE treatment population and opened a new growth segment within pediatric thrombosis management
• In July 2025, Bristol Myers Squibb and Pfizer launched the Eliquis 360 Support Program in the United States, providing discounted access to apixaban for uninsured and cash-paying patients. The initiative improved affordability and accessibility of anticoagulant therapy, strengthening Eliquis’ market penetration in long-term venous thromboembolism management
• In March 2026, new clinical evidence from comparative studies showed that apixaban has a lower risk of clinically relevant bleeding compared to rivaroxaban in patients with acute venous thromboembolism, further reinforcing its position as a preferred first-line DOAC in treatment guidelines

SKU-54413